NT69L, a novel analgesic, shows synergy with morphine

Brain Research

Volumn 1294, Issue , 2009, Pages 22-28

  Boules, M ^a   Shaw, A ^a   Liang, Y ^a   Barbut, D ^b   Richelson, E ^a  

^a MAYO CLINIC   (United States)

^b Sarentis Therapeutics Inc   (United States)

Author keywords

Antinociception; Hot plate; Morphine; Neurotensin; Rat; Synergism

Indexed keywords

LEVOCABASTINE; M 8777; MORPHINE SULFATE; NEUROTENSIN; NEUROTENSIN 69L; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HOT PLATE TEST; MALE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; THERMAL PAIN;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HOT TEMPERATURE; MALE; MORPHINE; NEUROTENSIN; PAIN; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; TIME FACTORS;

RATTUS;

EID: 70049106921     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.07.086     Document Type: Article

References (50)

1. Adler M.W., Geller E.B., Rosow C.E., and Cochin J. The opioid system and temperature regulation. Annu. Rev. Pharmacol. Toxicol. 28 (1988) 429-449
2. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., and Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 156 (1999) 1646-1649
3. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J., and Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature 262 (1976) 607-609
4. Bolan E.A., Tallarida R.J., and Pasternak G.W. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J. Pharmacol. Exp. Ther. 303 (2002) 557-562
5. Boules, M., Richelson, E., NTS1 neurotensin receptor. In: S.J. Enna and D.B. Bylund (Eds.), xPharm, Elsevier, Inc. http://www.xpharm.com/citation?Article_ID = 146, New York City, 2004a.
6. Boules, M., Richelson, E., NTS2 neurotensin receptor. In: S.J. Enna and D.B. Bylund (Eds.), xPharm, Elsevier, Inc. http://www.xpharm.com/citation?Article_ID = 147, New York City, 2004b.
7. Boules, M., Richelson, E., NTS3 neurotensin receptor. In: S.J. Enna and D.B. Bylund (Eds.), xPharm, Elsevier, Inc http://www.xpharm.com/citation?Article_ID = 42295, New York City, 2004c.
8. Boules M., Fredrickson P., and Richelson E. Bioactive analogs of neurotensin. Peptides 27 (2006) 2523-2533
9. Bredeloux P., Costentin J., and Dubuc I. Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice. Behav. Brain Res. 175 (2006) 399-407
10. Carraway R., and Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248 (1973) 6854-6861
11. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Le Fur G., Ferrara P., and Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386 (1996) 91-94
12. Choi S.Y., Chae H.D., Park T.J., Ha H., and Kim K.T. Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation. Br. J. Pharmacol. 126 (1999) 1050-1056
13. Clineschmidt B.V., and McGuffin J.C. Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli. Eur. J. Pharmacol. 46 (1977) 395-396
14. Clineschmidt B.V., McGuffin J.C., and Bunting P.B. Neurotensin: antinocisponsive action in rodents. Eur. J. Pharmacol. 54 (1979) 129-139
15. Clineschmidt B.V., Martin G.E., and Veber D.F. Antinocisponsive effects of neurotensin and neurotensin-related peptides. Ann. N. Y. Acad. Sci. 400 (1982) 283-306
16. Dubuc I., Remande S., and Costentin J. The partial agonist properties of levocabastine in neurotensin-induced analgesia. Eur. J. Pharmacol. 381 (1999) 9-12
17. Dubuc I., Sarret P., Labbe-Jullie C., Botto J.M., Honore E., Bourdel E., Martinez J., Costentin J., Vincent J.P., Kitabgi P., and Mazella J. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci. 19 (1999) 503-510
18. Fauq A.H., Hong F., Cusack B., Tyler B.M., Pang Y.P., and Richelson E. Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel trryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry 9 (1998) 4127-4134
19. Gessner P.K. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105 (1995) 161-179
20. Gomes C., Svensson T.H., and Trolin G. Effects of morphine on central catecholamine turnover, blood pressure and heart rate in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 294 (1976) 141-147
21. Hermans E., and Maloteaux J.M. Mechanisms of regulation of neurotensin receptors. Pharmacol. Ther. 79 (1998) 89-104
22. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51 (1994) 199-214
23. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
24. Leza J.C., Lizasoain I., and Lorenzo P. H1- and H2-histamine receptor blockers and opiate analgesia in mice. Methods Find. Exp. Clin. Pharmacol. 12 (1990) 671-678
25. Lutfy K., Shen K.Z., Woodward R.M., and Weber E. Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res. 731 (1996) 171-181
26. Luttinger D., Burgess S.K., Nemeroff C.B., and Prange A.J. The effects of chronic morphine treatment on neurotensin-induced antinociception. Psychopharmacology (Berl) 81 (1983) 10-13
27. Maeno H., Yamada K., Santo-Yamada Y., Aoki K., Sun Y.J., Sato E., Fukushima T., Ogura H., Araki T., Kamichi S., Kimura I., Yamano M., Maeno-Hikichi Y., Watase K., Aoki S., Kiyama H., Wada E., and Wada K. Comparison of mice deficient in the high- or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reveals a novel function for Ntsr2 in thermal nociception. Brain Res. 998 (2004) 122-129
28. Mazella J., Chabry J., Kitabgi P., and Vincent J.P. Solubilization and characterization of active neurotensin receptors from mouse brain. J. Biol. Chem. 263 (1988) 144-149
29. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., and Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 16 (1996) 5613-5620
30. Morgan C.J., Mofeez A., Brandner B., Bromley L., and Curran H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29 (2004) 208-218
31. Nemeroff C.B., Osbahr A.J., Manberg P.J., Ervin G.N., and Prange A.J. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 5368-5371
32. Nishiyama T. Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test. Eur. J. Pharmacol. 395 (2000) 203-210
33. Pettibone D.J., Hess J.F., Hey P.J., Jacobson M.A., Leviten M., Lis E.V., Mallorga P.J., Pascarella D.M., Snyder M.A., Williams J.B., and Zeng Z. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther. 300 (2002) 305-313
34. Rumore M.M., and Schlichting D.A. Analgesic effects of antihistaminics. Life Sci. 36 (1985) 403-416
35. Sarret P., Krzywkowski P., Segal L., Nielsen M.S., Petersen C.M., Mazella J., Stroh T., and Beaudet A. Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central nervous system. J. Comp. Neurol. 461 (2003) 483-505
36. Sarret P., Perron A., Stroh T., and Beaudet A. Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system. J. Comp. Neurol. 461 (2003) 520-538
37. Sarret P., Esdaile M.J., Perron A., Martinez J., Stroh T., and Beaudet A. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J. Neurosci. 25 (2005) 8188-8196
38. Schotte A., and Leysen J.E. Further characterization of neurotensin binding in the rat brain: levocabastine-displaceable neurotensin binding sites are not histamine-H1 receptors. Biochem. Pharmacol. 38 (1989) 3891-3893
39. Stiller C.O., Gustafsson H., Fried K., and Brodin E. Opioid-induced release of neurotensin in the periaqueductal gray matter of freely moving rats. Brain Res. 774 (1997) 149-158
40. Tanaka K., Masu M., and Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4 (1990) 847-854
41. Tershner S.A., and Helmstetter F.J. Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray. Brain Res. 865 (2000) 17-26
42. Tyler B.M., Cusack B., Douglas C.L., Souder T., and Richelson E. Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Res. 792 (1998) 246-252
43. Tyler B.M., Groshan K., Cusack B., and Richelson E. In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine, antagonize neurotensin-mediated antinociception. Brain Res. 787 (1998) 78-84
44. Tyler-McMahon B.M., Boules M., and Richelson E. Neurotensin: peptide for the next millennium. Regul. Pept. 93 (2000) 125-136
45. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., and Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur. J. Pharmacol. 390 (2000) 107-111
46. Vincent J.P. Neurotensin receptors: binding properties, transduction pathways, and structure. Cell. Mol. Neurobiol. 15 (1995) 501-512
47. Vincent J.P., Mazella J., and Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol.Sci. 20 (1999) 302-309
48. Vita N., Chalon P., Donat F., Bachy A., Kaghad M., Guillemot M., Thurneyssen O., Bonnin J., Delpech B., Soubrie P., Le Fur G., Caput D., and Ferrara P. Molecular cloning and characterization of a new human neurotensin binding site that recognizes levocabastine. Soc. Neurosci. 23 (1997) 94
49. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D., Le Fur G., Ferrara P., and Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 317 (1993) 139-142
50. Vita N., Oury-Donat F., Chalon P., Guillemot M., Kaghad M., Bachy A., Thurneyssen O., Garcia S., Poinot-Chazel C., Casellas P., Keane P., Le Fur G., Maffrand J.P., Soubrie P., Caput D., and Ferrara P. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur. J. Pharmacol. 360 (1998) 265-272